Pure Global
NCT05192213

Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock

Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock: a Randomized Clinical Study (VITAMIN TRIAL)
Hospital Sirio-Libanes·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Sepsis,Septic Shock
Drug/Device/Intervention
Vitamin C
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hospital Sirio-Libanes
Location
Fortaleza,Passos,Maringá,Barretos,Sao Paulo, Brazil
Timeline & enrollment
Phase
Phase 3
Start date
Aug 01, 2021
End date
Dec 20, 2023
Enrollment
1090 participants
Primary outcome

28-day Mortality

Summary

A great interest exists regarding substances with an immunomodulatory effect for sepsis
 patients. Recent data have shown that intravenous vitamin C, together with corticosteroids
 and thiamine, could prevent progressive organ dysfunction and reduce vasopressor use in
 patients with severe sepsis and septic shock. Its effect on mortality, on the other hand, is
 yet to be demonstrated. The Vitamins study aims to conclusively determine, through its
 prospective, multicentre and double-blinded design including 1090 patients, wether Vitamin C,
 Thiamine and Hydrocortisone in combination can reduce mortality in patients with septic
 shock.

ICD-10 classifications
Septic shockOther sepsisOther specified sepsisSepsis, unspecifiedSepsis due to other specified staphylococcus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05192213
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05192213 through Pure Global AI's free database. This Phase 3 trial is sponsored by Hospital Sirio-Libanes and is currently Recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 1090 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.